Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Maurizio Valeriani

Radiotherapy in Metastatic Castration Resistant Prostate Cancer Patients With Oligo-Progression During Abiraterone-Enzalutamide Treatment: A Mono-Institutional Experience

Radiation Oncology

English

Related publications

Enzalutamide and Abiraterone in the Treatment of Metastatic Castration-Resistant Prostate Cancer After Chemotherapy

Klinicka Onkologie

Oncology

2016

English

Pharmacoeconomic Evaluation of Enzalutamide, Abiraterone and Cabazitaxel for the Treatment of Post-Chemotherapy Patients With Metastatic Castration-Resistant Prostate Cancer

Medical Technologies. Assessment and Choice (Медицинские технологии. Оценка и выбор)

2018

English

Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide

Clinical Medicine Insights: Oncology

Oncology

2013

English

Initial Experience of the Enzalutamide Treatment for Castration-Resistant Prostate Cancer

Japanese Journal of Urology

Urology

2016

English

Abiraterone in Metastatic Castration-Resistant Prostate Cancer: Efficacy and Safety in Unselected Patients

Cancer Treatment and Research Communications

Cancer Research

Oncology

2018

English

TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer

Clinical Cancer Research

Cancer Research

Oncology

2018

English

Mp52-11 Association of Dose Reduction of Abiraterone Acetate Plus Prednisone or Enzalutamide and Psa Progression in Veterans With Metastatic Castration Resistant Prostate Cancer

Journal of Urology

Urology

2018

English

Prostate-Specific Antigen Decline After 4 Weeks of Treatment With Abiraterone Acetate and Overall Survival in Patients With Metastatic Castration-Resistant Prostate Cancer

European Urology

Urology

2016

English

Budget Impact Analysis of Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer From a u.s. Payer Perspective

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Maurizio Valeriani

Radiotherapy in Metastatic Castration Resistant Prostate Cancer Patients With Oligo-Progression During Abiraterone-Enzalutamide Treatment: A Mono-Institutional Experience

Related publications

Enzalutamide and Abiraterone in the Treatment of Metastatic Castration-Resistant Prostate Cancer After Chemotherapy

Pharmacoeconomic Evaluation of Enzalutamide, Abiraterone and Cabazitaxel for the Treatment of Post-Chemotherapy Patients With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide

Initial Experience of the Enzalutamide Treatment for Castration-Resistant Prostate Cancer

Abiraterone in Metastatic Castration-Resistant Prostate Cancer: Efficacy and Safety in Unselected Patients

TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer

Mp52-11 Association of Dose Reduction of Abiraterone Acetate Plus Prednisone or Enzalutamide and Psa Progression in Veterans With Metastatic Castration Resistant Prostate Cancer

Prostate-Specific Antigen Decline After 4 Weeks of Treatment With Abiraterone Acetate and Overall Survival in Patients With Metastatic Castration-Resistant Prostate Cancer

Budget Impact Analysis of Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer From a u.s. Payer Perspective